Astrotech is a science and technology development and commercialization company that launches, manages, and builds scalable companies based on innovative technology in order to maximize shareholder value. 1st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. AgLAB is developing chemical analyzers for use in the agriculture market. BreathTech is developing a breath analysis tool to provide early detection of lung diseases. Astrotech is headquartered in Austin, Texas.

Company profile
Ticker
ASTC
Exchange
Website
CEO
Thomas Boone Pickens
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Agilent • Perkinelmer • Bio-Rad Laboratories • Waters • Avantor • Illumina • Mettler-Toledo International • Bruker • Coherent • Seer ...
Former names
ASTROTECH Corp \WA\, SPACEHAB INC \WA\
SEC CIK
Corporate docs
Subsidiaries
1) Spacehab Orbital Transportation, Inc. • 2) Astrogenetix, Inc. • 3) 1st Detect Corporation • 4) Agriculture Technology Corporation • 5) Medikinetix, Inc. • 6) Astral Images Corporation • 7) Astrotech Technologies, Inc. • 8) BreathTech Corporation • 9) AgLAB Inc. ...
IRS number
911273737
ASTC stock data
News

12 Industrials Stocks Moving In Wednesday's After-Market Session
10 Aug 22
Stocks That Hit 52-Week Lows On Thursday
30 Jun 22
12 Industrials Stocks Moving In Monday's After-Market Session
27 Jun 22
12 Industrials Stocks Moving In Thursday's After-Market Session
16 Jun 22
10 Industrials Stocks Moving In Thursday's Pre-Market Session
16 Jun 22
Investment data
Securities sold
Number of investors
Calendar
13 May 22
12 Aug 22
30 Jun 23
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 21 | Jun 20 | Jun 19 | Jun 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 28.35M | 28.35M | 28.35M | 28.35M | 28.35M | 28.35M |
Cash burn (monthly) | 608K | 305.83K | 715.67K | 701.58K | 560K | 643.25K |
Cash used (since last report) | 2.68M | 1.35M | 3.15M | 3.09M | 2.47M | 2.83M |
Cash remaining | 25.67M | 27M | 25.2M | 25.26M | 25.88M | 25.51M |
Runway (months of cash) | 42.2 | 88.3 | 35.2 | 36.0 | 46.2 | 39.7 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Jul 22 | Wilkinson Thomas Wiley | Common Stock | Grant | Acquire A | No | No | 0 | 29,070 | 0 | 273,990 |
22 Jul 22 | James Frank Becker | Common Stock | Grant | Acquire A | No | No | 0 | 4,845 | 0 | 54,845 |
22 Jul 22 | Daniel T Russler Jr | Common Stock | Grant | Acquire A | No | No | 0 | 29,070 | 0 | 207,695 |
15 Apr 22 | Eric Stober | Common Stock | Sale back to company | Dispose D | No | No | 2.02 | 233,332 | 471.33K | 219,963 |
Institutional ownership, Q1 2022
12.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 6 |
Closed positions | 3 |
Increased positions | 1 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 3.74M |
Total shares | 6.52M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BML Investment Partners | 2.59M | $0 |
Vanguard | 1.55M | $1.12M |
BLK Blackrock | 727.5K | $525K |
Intracoastal Capital | 465.12K | $1.25M |
Geode Capital Management | 369.54K | $266K |
Marquette Asset Management | 276.68K | $199K |
STT State Street | 155.96K | $112K |
Renaissance Technologies | 88.6K | $64K |
NTRS Northern Trust | 83.59K | $60K |
VIRT Virtu Financial | 77.49K | $56K |
Financial report summary
?Risks
- We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future.
- Our business units are in development stage. They have earned limited revenues and it is uncertain whether they will earn any revenues in the future or whether any of them will ultimately be profitable.
- We may not be able to successfully develop the BreathTest-1000 or any other new products or services.
- We face various risks related to health epidemics, pandemics and similar outbreaks, which may have material adverse effects on our business, financial position, results of operations, and/or cash flows.
- Our success depends significantly on the establishment and maintenance of successful relationships with our customers.
- Third parties may claim we are infringing their intellectual property rights, and we could suffer significant litigation or licensing expenses or be prevented from selling products.
- Our ongoing success is dependent upon the continued availability of certain key employees.
- Our operating results may be adversely affected by increased competition.
- Our insurance coverage may be inadequate to cover all significant risk exposures.
- Increased cybersecurity requirements, vulnerabilities, threats, and more sophisticated and targeted computer crime could pose a risk to our systems, networks, products, services, and data.
- Our facilities located in Austin are susceptible to damage caused by hurricanes or other natural disasters.
- If we are unable to anticipate technological advances and customer requirements in the commercial and governmental markets, our business and financial condition may be adversely affected.
- Significant safety concerns could arise for our BreathTest-1000 product, which could have a material adverse effect on our future revenues and financial condition.
- We incur substantial upfront, non-reimbursable costs in preparing proposals to bid on contracts or to receive research and development grants that we may not be awarded.
- A failure of a key information technology system, process, or site could have a material adverse impact on our ability to conduct business.
- A sale of a substantial number of shares of the common stock may cause the price of our common stock to decline.
- We are a smaller reporting company and, as a result of the reduced disclosure and governance requirements applicable to such companies, our common stock may be less attractive to investors.
- We are required to evaluate the effectiveness of our internal control over financial reporting on an annual basis and publicly disclose any material weaknesses in our controls. Any adverse results from such evaluation could result in a loss of investor confidence in our financial reports and significant expense to remediate, and ultimately could have an adverse effect on our stock price.
- We can sell additional shares of common stock without consulting shareholders and without offering shares to existing shareholders, which would result in dilution of shareholders’ interests in the Company and could depress our stock price.
- Our products and operations are subject to extensive governmental regulation, and failure to comply with applicable requirements could cause our business to suffer.
- Failure to obtain clearance or authorization for the BreathTest-1000, or other delays in the development of the BreathTest-1000, would adversely affect our ability to grow our business.
- FDA’s policy with respect to Emergency Use Authorizations is evolving and may limit the ability for medical products, including the BreathTest-1000, to be eligible for commercialization under an Emergency Use Authorization.
- Modifications to our products may require new 510(k) clearances, de novo submissions, or pre‑market approvals, or may require us to cease marketing or recall the modified products until clearances are obtained.
- If we or our third‑party suppliers fail to comply with the FDA’s good manufacturing practice regulations or fail to adequately, timely, or sufficiently respond to an FDA Form 483 or subsequent Warning Letter, this could impair our ability to market our products in a cost‑effective and timely manner and could result in FDA enforcement action.
- A recall of our product, or the discovery of serious safety issues with our product, could have a significant adverse impact on us.
- We may be liable if the FDA or other U.S. enforcement agencies determine we have engaged in the off‑label promotion of our products or have disseminated false or misleading labeling or promotional materials.
- Legislative or regulatory healthcare reforms may make it more difficult and costly for us to obtain reimbursement for our products or regulatory clearance or approval of our future products, and to produce, market and distribute those products after clearance or approval is obtained.
Management Discussion
- Revenue – Total revenue decreased by $154 thousand, or 32%, to $334 thousand for the fiscal year ended June 30, 2021, compared to $488 thousand for the fiscal year ended June 30, 2020. Substantially all of the fiscal year 2021 and 2020 revenue was from the sales of our TRACER 1000 units to DHL (Deutsche Post AG). The decrease in revenue was caused by pandemic-related delays in the delivery of certain microchips used in the production of our TRACER 1000 systems. Even though production has resumed, we continue to see impacts to the supply chain from the microchip shortages.
- Cost of Revenue and Gross Profit – Cost of revenue is comprised of labor, materials, shipping, warranty reserve, and overhead allocation. Gross profit is comprised of revenue less cost of revenue. Cost of revenue decreased $151 thousand, or 34%, for the fiscal year ended June 30, 2021, compared to the year ended June 30, 2020. Gross profit decreased $3 thousand and gross margin increased 3% during the fiscal year ended June 30, 2021, compared to the year ended June 30, 2020. We expect that gross margin will continue to improve as we increase production and benefit from associated volume discounts, and as we further refine our technology.
- Operating Expenses – Our operating expenses decreased $207 thousand, or 3%, during the fiscal year ended June 30, 2021, compared to the fiscal year ended June 30, 2020. Significant changes to operating expenses include the following:
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
appoint, appointed, appointment, Auto, boost, Burton, Cantwell, CBD, CFO, Committee, Cortez, death, demonstrate, director, disagreement, earlier, environment, Eric, family, Hinojosa, Jaime, joined, joining, knowledge, LLP, matter, McCumber, member, nutraceutical, oil, ORLY, people, potency, resignation, Ronald, salary, served, Stober, strike, THC, today, Treasurer, vesting
Removed:
generated, incorporated, reference
Financial reports
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Jul 22
8-K
Astrotech Appoints Jim Becker to Board of Directors
23 Jun 22
8-K
Other Events
23 Jun 22
8-K
Astrotech Reports Third Quarter of Fiscal Year 2022 Financial Results
13 May 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Apr 22
8-K
Departure of Directors or Certain Officers
26 Apr 22
8-K/A
Departure of Directors or Certain Officers
18 Apr 22
8-K
Departure of Directors or Certain Officers
6 Apr 22
8-K
Submission of Matters to a Vote of Security Holders
30 Mar 22
8-K
Astrotech Reports Second Quarter of
11 Feb 22
Registration and prospectus
S-8
Registration of securities for employees
21 Oct 21
424B5
Prospectus supplement for primary offering
9 Apr 21
FWP
Free writing prospectus
8 Apr 21
FWP
Free writing prospectus
7 Apr 21
424B5
Prospectus supplement for primary offering
7 Apr 21
S-3
Shelf registration
3 Mar 21
424B5
Prospectus supplement for primary offering
12 Feb 21
424B5
Prospectus supplement for primary offering
18 Dec 20
424B5
Prospectus supplement for primary offering
29 Oct 20
424B4
Prospectus supplement with pricing info
22 Oct 20
Other
EFFECT
Notice of effectiveness
16 Mar 21
CORRESP
Correspondence with SEC
10 Mar 21
UPLOAD
Letter from SEC
9 Mar 21
EFFECT
Notice of effectiveness
22 Oct 20
CORRESP
Correspondence with SEC
19 Oct 20
CORRESP
Correspondence with SEC
18 Oct 20
CORRESP
Correspondence with SEC
8 Sep 20
UPLOAD
Letter from SEC
12 Jul 20
EFFECT
Notice of effectiveness
9 Nov 18
CORRESP
Correspondence with SEC
5 Nov 18
Ownership
4
ASTROTECH / Daniel T Russler Jr ownership change
25 Jul 22
4
ASTROTECH / Thomas Wiley Wilkinson ownership change
25 Jul 22
4
ASTROTECH / James Frank Becker ownership change
25 Jul 22
3
ASTROTECH / James Frank Becker ownership change
19 Jul 22
3
ASTROTECH / Jaime Hinojosa ownership change
21 Apr 22
4
ASTROTECH / Eric Stober ownership change
18 Apr 22
4
ASTROTECH / Thomas Boone Pickens III ownership change
18 Apr 22
4
ASTROTECH / Thomas Wiley Wilkinson ownership change
18 Apr 22
4
ASTROTECH / Daniel T Russler Jr ownership change
18 Apr 22
4
ASTROTECH / RONALD W CANTWELL ownership change
18 Apr 22
Reddit threads
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - May 11th, 2022
11 May 22
Here Comes The RUN $HYMC
28 Mar 22
Daily Discussion Thread - February 14th, 2022
14 Feb 22
Daily Plays November 12, 2021
11 Nov 21
Daily Discussion Thread - November 11th, 2021
11 Nov 21
Daily Discussion Thread - November 10th, 2021
10 Nov 21
Daily Discussion Thread - November 9th, 2021
9 Nov 21
Daily Plays November 02, 2021
1 Nov 21
Daily Discussion Thread - September 21st, 2021
21 Sep 21